SV2A Inhibitors
6 drugsAbout SV2A
Synaptic Vesicle Glycoprotein 2A (SV2A) is a transmembrane protein in the brain that regulates neurotransmitter release. Its role in neurotransmitter release makes it a compelling target for therapeutic intervention.
Human genetic studies provide strong validation for SV2A as a therapeutic target (max score 0.84). Genetic variants are linked to skeletal abnormalities (score 0.84), developmental and epileptic encephalopathy (score 0.76), and type 2 diabetes (score 0.58), suggesting activation may be beneficial.
SV2A is targeted by 6 FDA-approved small molecule drugs, including LEVETIRACETAM (KEPPRA) and BRIVIACT. These drugs are used for CNS disorders and other therapeutic areas.
Strategic Insights
ℹ️ How we calculate- White space opportunity in Brain Tumors with only 2 trials.
Human Genetic Evidence Strong
SV2A has strong genetic support with a max score of 0.84 across 13 diseases.
Strong genetic support suggests SV2A-targeting drugs have a higher probability of clinical success.
💡 Why activation?
- • Loss-of-function variants increase disease risk (OR > 1) — restoring function may help
- • 100% directional consistency across 1 traits
- • Strong signal in nervous system disease, genetic, familial or congenital disease pathways
Cross-Disease Effects
Trade-off: LowDirection of Effect
100% alignedEvidence Across Diseases
13 totalGWAS and other genetic studies link SV2A to 13 diseases.
Loss-of-function causes disease; activation may help
🔗 Colocalization Evidence 20 strong
max H4: 1.00eQTL/pQTL signals for SV2A colocalize with these GWAS traits, providing causal evidence that gene expression changes drive disease risk.
Understanding these scores
Association Score (0-1): Combines all evidence types (genetic, literature, drugs, animal models). Higher = more evidence linking target to disease. This is a ranking heuristic, not a confidence score.
L2G Score: Open Targets uses a machine learning model (Locus-to-Gene) to predict which gene is causal at each GWAS locus. L2G=0.5 means ~50% probability of being the causal gene. Only associations with L2G > 0.05 are included.
Odds Ratio (OR): From gene burden studies (UK Biobank, AstraZeneca PheWAS). Measures how loss-of-function variants affect disease risk. OR<1 = protective (inhibiting target may help), OR>1 = risk (losing function causes disease).
Beta (β): Effect size for continuous traits. β<0 = protective, β>0 = risk.
Clinical Translation (~1.8x): Based on Nelson et al. 2015: drug targets with genetic evidence have ~2x higher success rates in clinical trials. We estimate: Strong support (score ≥0.7) → ~1.8x, Moderate (0.3-0.7) → ~1.3x, Weak → baseline.
Colocalization (H4): Tests whether a GWAS signal and an eQTL/pQTL signal share the same causal variant. H4 is the posterior probability that both traits are associated AND share a causal variant. H4 > 0.8 = strong evidence that gene expression/protein levels drive disease risk. This links genetic variation → gene expression → disease, supporting the target-disease connection.
Top Drugs
Four companies have approved drugs targeting SV2A, including ZYDUS PHARMS USA INC and UCB INC.
The competitive landscape indicates moderate market concentration, suggesting potential entry barriers.
| Drug | Company | Approved | Indications |
|---|---|---|---|
| BRIVARACETAM | HAINAN POLY | 2022 | 1 |
| BRIVIACT | UCB INC | 2016 | 1 |
| KEPPRA XR | UCB INC | 2008 | 1 |
Drug Modality Landscape
Modalities
Routes of Administration
SV2A is amenable to small molecule drugs, with oral options available for convenient dosing.
The modality landscape suggests an opportunity to develop non-small molecule drugs targeting SV2A.
Clinical Trials 261 trials
Completion by Phase
| Phase | Total | Completed | Failed | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 52 | 41 | 3 | 6 | 93% |
| Phase 2 | 69 | 38 | 16 | 15 | 70% |
| Phase 3 | 95 | 64 | 10 | 21 | 86% |
| Phase 4 | 45 | 25 | 9 | 8 | 74% |
Top Sponsors
By Modality
Phase 3 Readout Calendar Pro
2 Phase 3 trials testing approved SV2A drugs across all sponsors.
Coverage: trials whose intervention is an approved drug targeting SV2A. Pre-approval candidates with development codes (e.g. AZD0901, MK-7240) are not yet linked. Anchored on CT.gov primary completion date.
Drug Approval Timeline (1999 - 2022)
The first SV2A-targeting drug was approved in 1999 (KEPPRA), with the most recent in 2022 (BRIVARACETAM).
The approval timeline indicates continued interest in SV2A as a drug target.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 4 companies competing
- • Market share by company
Full Drug Portfolio
- • All 6 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 6-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Competition: High (15 sponsors)
- • White space: 10 underexplored indications
- • Success rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Calculate These Metrics
Target Attractiveness Score
A 0-100 score based on trial activity, sponsor diversity, and completion rates. Calculated from 173 clinical trials targeting SV2A.
Completion rate: Percentage of trials that reached their planned endpoint. Trials terminated early, withdrawn, or suspended are not counted—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Highly Attractive (80+): High trial activity, many sponsors, strong completion rates
- Attractive (60-79): Good trial activity and validation
- Moderate (40-59): Moderate interest from sponsors
- Low (under 40): Limited trial activity or validation concerns
Strategic Insights
Auto-generated insights based on trial analytics including competition intensity, white space opportunities, modality shifts, and failure patterns. We analyze trial sponsors, phases, indications, and outcomes.
Risk Signals
- High Competition: Many sponsors competing for this target (may reduce market opportunity)
- High Failure Risk: Low trial completion rates suggest development challenges
- Low Validation: Limited trial activity or poor outcomes indicate uncertain viability
- White Space Available: Underexplored indications present opportunities